

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Garcia-Martinez, J. Victor		POSITION TITLE Professor of Internal Medicine	
eRA COMMONS USER NAME (credential, e.g., agency login) VGARCI			
EDUCATION/TRAINING (<i>Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.</i>)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Instituto Tecnologico y de Estudios, Superiores de Monterray, Mexico	B.Sc.	1979	Chemistry
Georgetown University, Washington, D.C.	Ph.D.	1984	Chemistry/Biochemistry
National Cancer Institute, NIH	Fellow	1984-85	Biology/Immunology
Massachusetts Institute of Tech., Boston, MA	Fellow	1985-87	Cell Biology
Fred Hutchinson Cancer Ctr., Seattle, WA	Res. Assoc.	1987-92	Human Gene Therapy

A. Positions and Honors:

- 1992 – 1999 **Assistant Member, Associate Member**, Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN
- 1999 – 2002 **Associate Professor (Tenured)**, Departments of Internal Medicine and Microbiology, Division of Infectious Diseases, UT Southwestern Medical Center at Dallas, Dallas, TX
- 2002 – 2009 **Professor (Tenured)**, Departments of Internal Medicine and Microbiology, Division of Infectious Diseases, UT Southwestern Medical Center at Dallas, Dallas, TX
- 2009 – Present **Professor**, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC

Other Professional Activities:

- 1996-1999 Medical Biochemistry Study Section, NIH, Member
- 2001 Chair, ZRGI AARR-5 03 M Special Review Panel
- 1999-2005 AARC-1 Study Section, NIH, Member
- 2009-Present National Board of Directors SACNAS

B. Selected Publications:

Garcia JV and Miller AD. Nef induces cell surface CD4 downregulation by a serine phosphorylation independent pathway. *Nature* 350:508-511, 1991.

Anderson SJ, Lenburg M, Landau NR, **Garcia JV**. The cytoplasmic domain of CD4 is sufficient for its down-regulation from the cell surface by HIV-1 Nef. *J Virol* 68:3092-3101, 1994.

Adams M, Sharmeen L, Kimpton J, Romeo JR, **Garcia JV**, Peterlin BM, Groudine M, Emerman M. Cellular latency in HIV-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcription. *Proc Natl Acad Sci USA* 91:3862-3866, 1994.

Constantinescu SN, Croze E, Murti A, Wang C, Basu L, Hollander D, Russell-Harde D, Betts M, **Garcia JV**, Mullersman JE, Pfeffer LM. Expression of signaling specificity of the IFNR-1 chain of the type I IFN receptor complex. *Proc Natl Acad Sci* 92:10487-10491, 1995.

Luo T, Anderson SJ, **Garcia JV**. Inhibition of Nef- and phorbol ester-induced CD4 degradation by macrolide antibiotics. *J Virol* 70:1527-1534, 1996.

Luo T, Downing JR, and **Garcia JV**. Induction of phosphorylation of human immunodeficiency virus type 1 Nef and enhancement of CD4 downregulation by phorbol myristate acetate. *J. Virology* 71:2535-2539, 1997.

O'Neill E, Douglas JL, Chien M, and **Garcia JV**. Open Reading Frame 26 of Human Herpesvirus 8 Encodes a TPA- and Butyrate-Inducible 32 kDa Protein Expressed in a Body Cavity-Based Lymphoma Cell Line. *J. Virol.* 71:4791-4797, 1997.

Chien M, Foster JL, Douglas, JL, and **Garcia, JV**. The Amphotropic murine leukemia virus receptor gene encodes a 71-Kilodalton protein that is induced by phosphate depletion. *J. Virol.* 71:4564-4570, 1997.

Luo L, Douglas JL, Livingston, RL, and **Garcia JV**. Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems. *Virology* 241:224-233, 1998.

Douglas J, Kelly P, Evans JT and **Garcia JV**. Efficient Transduction of Human Lymphocytes and CD34⁺ Cells Via HIV-Based Gene Transfer Vectors. *Human Gene Therapy* 10:935-945, 1999.

Gatlin J, Douglas J, Evans JT, Collins RH, Wendel GD and **Garcia JV**. In vitro Selection of Lentivirus Vector Transduced Human CD34⁺ Cells. *Human Gene Therapy* 11,1949-1957, 2000.

Evans JT and **Garcia JV**. Lentivirus Vector Mobilization and Spread by the Human Immunodeficiency Virus. *Human Gene Therapy* 11,2331-2339, 2000.

Evans JT, Cravens P., Lipsky PE and **Garcia JV**. Differentiation and Expansion of Lentivirus-Vector Marked Dendritic Cells Derived from Human CD34⁺ Cells. *Human Gene Therapy* 11, 2483-2492, 2000.

Gatlin J, Padgett A, Melkus MW, Kelly PF and **Garcia JV**. Long-Term Engraftment of NOD/SCID Mice with Human CD34⁺ Cells Transduced by a Self-Inactivating HIV-1 Vector. *Human Gene Ther.* 12, 1079-1089, 2001.

Gatlin J, Melkus MW, Padgett A, Kelly PF and **Garcia JV**. Engraftment of NOD/SCID mice with human CD34⁺ cells transduced by concentrated oncoretroviral vector particles pseudotyped with the feline endogenous virus (RD114) envelope glycoprotein. *J. Virol.* 75, 9995-9999, 2001. PMID: PMC114573.

Evans JT, Cravens P, Gatlin J, Kelly P, Lipsky PE and **Garcia JV**. Pre-Clinical Evaluation of an In Vitro Selection Protocol for the Enrichment of Transduced CD34⁺ Cell Derived Human Dendritic Cells. *Gene Therapy* 8, 1427-1435, 2001.

Arora VA, Molina RP, Foster JL, Blakemore JL, Chernoff J, Fredericksen BL and **Garcia JV**. Lentivirus Nef Specifically Activates Pak2. *J. Virol.* 74, 11081-11087, 2000. PMID: PMC113188.

Luo T, Fredericksen, BL, Hasumi, K, Endo A, and **Garcia JV**. Human immunodeficiency Virus Type-1 Nef-Induced CD4 Cell Surface Downregulation Is Inhibited by Ikarugamycin. *J Virology* 75, 2488-2492, 2001. PMID: PMC114835.

Foster JF, Molina RP, Luo T, Arora VK, Huang Y, Ho D and **Garcia JV**. Genetic and Functional Diversity Amongst HIV-1 Subtype B Nef Primary Isolates. *J. Virology* 75, 1672-1680, 2001. PMID: PMC114076.

Arora, VK, Fredericksen BL, and **Garcia JV**. Nef: agent of cell subversion. *Microbes and Infection* 4m 189-199, 2002.

Fredericksen BL, Yao J, Luo T and **Garcia JV**. Inhibition of Endosomal/Lysosomal Degradation Increases the Infectivity of the Human Immunodeficiency Virus. *J. Virology.* 76, 11440-11446, 2002. PMID: PMC136743.

Wilund KR, Yi M, Champagna F, Arca M, Zuliana G, Fellin R, Ho YK, **Garcia JV**, Hobbs HH, Cohen JC. Molecular Mechanisms of Autosomal Recessive Hypercholesterolemia. *Human Mol. Genetics.* 11, 3019-30,2002.

Hamra FK, Gatlin JE, Chapman KM, Grellhesl DM, **Garcia JV**, Hammer RE and Garbers DL. Production of Transgenic Rats by Direct Germline Transmission. *Proc. Nat. Acad. Sci. USA* 99, 14931-14936, 2002. PMID: PMC137522.

Gatlin J, Melkus MW, Padgett A, Petroll WM, Cavanaugh D, **Garcia JV** and Jester JV. In Vivo Fluorescent Labeling of Corneal Wound Healing Fibroblasts. *Exp. Eye Res.* 76, 361-71, 2003.

Palucka AK, Gatlin JE, Blanck JP, Melkus MW, Clayton S, Ueno H, Kraus ET, Cravens P, Bennett L, Padgett-Thomas A, Marches F, Islas-Ohlmayer M, **Garcia JV** and Banchereau J. Human Dendritic Cell Subsets in NOD/SCID Mice Engrafted with CD34⁺ Hematopoietic Progenitors. *Blood*. 102, 3302-3310, 2003.

Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, Melkus MW, Cravens PD, Martin M del P, Netto G, and **Garcia JV**. Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34⁺ Cells with Epstein-Barr Virus. *J. Virol.* 78, 13891-13900, 2004. PMID: PMC533956.

Cravens PD, Melkus MW, Padgett-Thomas A, Islas-Ohlmayer M, Martin MP and **Garcia JV**. *In vivo* modeling of human dendritic cell development, differentiation and function: phenotypic and functional analysis during the steady state and acute response to endotoxin. *Stem Cells*. 23, 264-278, 2005.

Wei, B.L., P.W. Denton, E. O'Neill, T. Luo, J. L. Foster, and **Garcia JV**. Inhibition of Lysosome and proteasome function enhances human immunodeficiency virus type I infection. *J. Virol.* 79: 5705-5712, 2005. PMID: PMC1082736.

Raney A, Kuo LS, Baugh LL, Foster JL and **Garcia JV**. Reconstitution and molecular analysis of an active Nef/PAK-2 complex. *J. Virology*. 79, 12732-12741, 2005. PMID: PMC1235864.

Wei B, Arora VK, Raney A, Kuo L, Xiao G-H, O'Neill E, Testa JR, Foster JL and **Garcia JV**. Activation of p21-activated kinase by human immunodeficiency virus type-1 Nef induces merlin phosphorylation. *J. Virology*. 79, 14976-14980, 2005. PMID: PMC1287594.

O'Neill E, Kuo LS, Krisko JF, Tomchick DR, **Garcia JV**, and Foster JL. Dynamic evolution of the human immunodeficiency virus type 1 pathogenic factor, Nef. *J. Virology*. 80, 1311-1320, 2006. PMID: PMC1346962.

Agopian J, Wei BL, **Garcia JV**, and Gabuzda D. A Hydrophobic Binding Surface on the Human Immunodeficiency Virus Type 1 Nef Core Is Critical for Association with p21-Activated Kinase 2. *J. Virology*. 80, 3050-3061, 2006. PMID: PMC1395437.

Foster, JL and **Garcia JV**. HIV Pathogenesis: Nef loses control. *Cell*. 125, 1034-1035, 2006.

Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno F, Wege AK, Hasse AT, and **Garcia JV**. Humanized mice mount specific adaptive and innate immune response to EBV and TSST-1. *Nature Medicine*. 12:1316-1322, 2006.

O'Neill E, Baugh LL, Novitsky VA, Essex ME and **Garcia JV**. 2006. Intra- and intersubtype alternative Pak2-activating structural motifs of HIV-1 Nef. *J. Virology*. 80: 8824-8829, 2006. PMID: PMC1563850.

Sun Z, Denton PW, Estes JD, Othieno F, Wei B, Wege AK, Melkus MW, Padgett-Thomas A, Zupancic M, Haase AT and **Garcia JV**. Intrarectal transmission, systemic infection and CD4 T cell depletion in humanized mice infected with HIV-1. *J. Exp. Med.* 204: 705-714, 2007. PMID: PMC2118553.

Raney A, Shaw AY, Foster JL and **Garcia JV**. Structural constraints on human immunodeficiency virus type 1 Nef function. *Virology*. 368, 7-16, 2007.

Wege A, Denton PD, Estes JD and **Garcia JV**. Functional and phenotypic characterization of the humanized BLT mouse model. *Current Topics in Microbiology and Immunology*. 324:149-165, 2008.

Denton PW, Estes JD, Sun Z, Othieno F, Wei B, Wege AK, Powell DA, Payne D, Haase AT and **Garcia JV**. Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice. *PLoS Medicine* Vol. 5, No. 1, e16 doi:10.1371, 2008. PMID: PMC2194746.

Wang J, Shackelford JM, Selliah N, Shivers DK, O'Neill E, **Garcia JV**, Karupiah M, Weiner D, Yu X-F, Gabuzda D and Finkel TH. The HIV-1 Vif Protein Mediates degradation of Vpr and Reduces Vpr-Induced Cell

Cycle Arrest. *DNA and Cell Biology*. 27(5):267-77, 2008.

Buzina A, Lo M, Moffett A, Hotta A, Fussner E, Bharadwaj R, Pasceri P, **Garcia JV**, Bazett-Jones D, and Ellis J. β -globin LCR and intron elements cooperate and direct spatial reorganization for gene therapy. *PLoS Genetics*. 4(4):e1000051.doi:1.1371/journal.pgen.1000051, 2008.

Baugh LL, **Garcia JV**, Foster JL. Functional Characterization of the Human Immunodeficiency Type 1 Nef Acidic Domain. *J. Virology*. 82(19):9657-67. PMID: PMC2546962, 2008.

Foster JL, **Garcia JV**. HIV-1 Nef: at the crossroads. *Retrovirology* 5:84, doi:10.1186/1742-4690-5-84 (2008).

Denton PW and **Garcia JV**. Novel humanized murine models for HIV research. *Curr HIV/AIDS Rep* 6(1):13-9 (2009).

C. Research Support: Ongoing

NIAID 5 R01 AI033331, "Nef Function," 06/01/07 – 05/31/11. J. Victor Garcia-Martinez, Ph.D., Principal Investigator. The focus of this competitive renewal grant is to implement a novel *in vivo* system of HIV infection developed in our laboratory to begin to dissect the individual contributions of the different *in vitro* activities of HIV-1 Nef to pathogenesis and disease progression.

NIH R01 AI073146-01A2, "Vaginal/Rectal HIV Transmission Model," 08/01/07 – 07/31/11. J. Victor Garcia-Martinez, Ph.D., Principal Investigator. The long-term goal of our laboratory is to investigate novel approaches to prevent HIV transmission by the use of antivirals and microbicides.

NIH NIAID 4R33 AI071940-3, "Implementation of a vaginal/rectal HIV transmission model to evaluate microbicides," 09/20/08 – 08/31/11. J. Victor Garcia-Martinez, Ph. D. Principal Investigator. The long term goal of this project is to study HIV transmission in a xenograft model of infection.

NIAID 5 R01 AI39416, "Gene Transfer System for AIDS Therapy," 12/01/03 – 11/30/09. J. Victor Garcia-Martinez, Ph.D., Principal Investigator. The long-term goal of this proposal is to develop gene therapy approaches to treat HIV disease.

NIH 1R21-AI068527-01, "Structural Plasticity of an HIV-1 Nef/Pak-2 Activating Surface," 08/01/06 – 07/31/09. J. Victor Garcia-Martinez, Ph.D., Principal Investigator. The studies proposed here will help elucidate the structural requirements for the activation of Pak-2 by Nef and will serve as the basis for future *in vivo* experiments aimed at characterizing its functional significance.

Pending

NIH 1R01AI079607-01A1 "Molecular Basis of Mucosal HIV Transmission," 07/01/09 – 06/31/13. J. Victor Garcia-Martinez, Ph.D., Principal Investigator. The long term-goal of our laboratory is to investigate novel approaches to prevent HIV transmission.

NIH "Modeling eradication of HIV infection in BLT mice," 03/01/2009 – 02/28/2014. J. Victor Garcia-Martinez, Ph.D., Principal Investigator (David M. Margolis, M.D., PI, University of N. Carolina Consortium). The long term goal of our project is to develop and implement an *in vivo* animal model in which novel protocols for HIV-1 eradication can be evaluated.

NIH "Topical antiretrovirals to prevent rectal HIV infection," 03/01/2009 – 02/28/2014. J. Victor Garcia-Martinez, Ph.D. (Ian McGowan, M.D., PI, Magee Womens Research Institute and Foundation Consortium). Our long term-goal is to investigate novel approaches to prevent HIV transmission by the use of topical microbicides.